TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04521140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection
Study: NCT02512159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drenovac handcrafted
Description: under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Healing
Description: Were handled as follows:~1. Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.~2. healing of skin ulcers were performed every 24 hours.~3. the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables.
Study: NCT04048083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental trainings
Description: Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-aided trainings
Description: Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-aided and mental trainings
Description: Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No trainings
Description: Healthy controls without any kind of training
Study: NCT03112551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adminstration of magnesium Sulphate for treatment of eclampsia
Description: A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adminstration of magnesium Sulphate for treatment of eclampsia
Description: A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
Study: NCT01386177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 125 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: 3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsules identical to MDMA or doxazosin
Study: NCT01972347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
Study: NCT01861197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib 500mg daily for 5 days on/ 2 day off until progression
Study: NCT02226484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
Study: NCT03829761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Description: Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
Study: NCT03645187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFERI
Description: FOLFERI regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folferi and celecoxib
Description: Folferi regimen and celecoxib
Study: NCT03184870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days
Study: NCT02649621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Extract Eye Drop (AMEED)
Description: Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
Study: NCT02545283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Participants will receive cytarabine 1 gram per square meter (g/m\^2) intravenous (IV) infusion for 5 days of every treatment cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Participants will receive cytarabine 1 gram per square meter (g/m\^2) intravenous (IV) infusion for 5 days of every treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
Study: NCT02399423

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight gain
Description: Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight gain
Description: Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
Study: NCT01426633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Trabectedin
Description: Combination therapy of gemcitabine and trabectedin
Study: NCT03701594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-based physical therapy group
Description: All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seated Rest
Description: Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise.
Study: NCT03749252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
Study: NCT00316277

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Management (SMM) of Prescription Opiate Abuse
Description: Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Management (EMM) of Prescription Opiate Abuse
Description: Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
Study: NCT00271115

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Kangaroo Holding
Description: Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
Study: NCT01383512

Intervention type: DEVICE
Group type: OTHER
Intervention: ARMEO Spring
Description: Use of the device 1 hour per day, 5 days per week during 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARMEO Spring
Description: Use of the device 1 hour per day, 5 days per week during 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self rehabilitation
Description: Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
Study: NCT04230564

Intervention type: DRUG
Intervention: azacitidine
Description: Patients taking azacitidine

Intervention type: DRUG
Intervention: venetoclax
Description: patients taking venetoclax

Intervention type: DRUG
Intervention: glasdegib
Description: patients taking glasdegib
Study: NCT00741429

Intervention type: DRUG
Intervention: Technosphere Insulin Inhalation Powder
Description: Subjects previously treated with Technosphere Insulin Inhalation Powder

Intervention type: DRUG
Intervention: Comparator
Description: Subjects previously treated with other anti-diabetic medications
Study: NCT01820624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03184870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days
Study: NCT01531894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 (afuresertib)
Description: Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
Study: NCT01642277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: 5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
Study: NCT03340376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin
Study: NCT00996684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The placebo control will be the microplasmin vehicle without the microplasmin.
Study: NCT04347018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRIUS
Description: This is a device that is designed based on movements planned virtually on a computer program. Then all the planned movements are embedded into the wire causing the wire to have the necessary bends to move every tooth into its pre-planned final position. This causes the pre-activated wire to consistently express a low force over a long period of time onto all the teeth. This allows the teeth to move into the final position and treatment progresses towards completion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BRIUS
Description: This is a device that is designed based on movements planned virtually on a computer program. Then all the planned movements are embedded into the wire causing the wire to have the necessary bends to move every tooth into its pre-planned final position. This causes the pre-activated wire to consistently express a low force over a long period of time onto all the teeth. This allows the teeth to move into the final position and treatment progresses towards completion